Logo image of ALSMA.PA

SMAIO SA (ALSMA.PA) Stock Fundamental Analysis

EPA:ALSMA - Euronext Paris - Matif - FR0014005I80 - Common Stock - Currency: EUR

4.04  0 (0%)

Fundamental Rating

3

ALSMA gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 54 industry peers in the Health Care Equipment & Supplies industry. The financial health of ALSMA is average, but there are quite some concerns on its profitability. ALSMA is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ALSMA has reported negative net income.
In the past year ALSMA has reported a negative cash flow from operations.
The reported net income has been mixed in the past 5 years: ALSMA reported negative net income in multiple years.
ALSMA had negative operating cash flow in 4 of the past 5 years.
ALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFALSMA.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 0 2M -2M 4M -4M

1.2 Ratios

ALSMA's Return On Assets of -14.21% is on the low side compared to the rest of the industry. ALSMA is outperformed by 62.26% of its industry peers.
With a Return On Equity value of -22.35%, ALSMA is not doing good in the industry: 60.38% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -14.21%
ROE -22.35%
ROIC N/A
ROA(3y)-2.24%
ROA(5y)-17.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ALSMA.PA Yearly ROA, ROE, ROICALSMA.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 0 200 400

1.3 Margins

With an excellent Gross Margin value of 88.45%, ALSMA belongs to the best of the industry, outperforming 92.45% of the companies in the same industry.
ALSMA's Gross Margin has declined in the last couple of years.
ALSMA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 88.45%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-4.68%
ALSMA.PA Yearly Profit, Operating, Gross MarginsALSMA.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 0 -200 -400

More info and screens

6

2. Health

2.1 Basic Checks

ALSMA does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALSMA has about the same amout of shares outstanding than it did 1 year ago.
ALSMA has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, ALSMA has a worse debt to assets ratio.
ALSMA.PA Yearly Shares OutstandingALSMA.PA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 1M 2M 3M 4M 5M
ALSMA.PA Yearly Total Debt VS Total AssetsALSMA.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 5M 10M 15M

2.2 Solvency

ALSMA has an Altman-Z score of 3.16. This indicates that ALSMA is financially healthy and has little risk of bankruptcy at the moment.
The Altman-Z score of ALSMA (3.16) is better than 69.81% of its industry peers.
ALSMA has a Debt/Equity ratio of 0.31. This is a healthy value indicating a solid balance between debt and equity.
With a Debt to Equity ratio value of 0.31, ALSMA perfoms like the industry average, outperforming 58.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Altman-Z 3.16
ROIC/WACCN/A
WACC7.75%
ALSMA.PA Yearly LT Debt VS Equity VS FCFALSMA.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 0 5M -5M 10M

2.3 Liquidity

A Current Ratio of 5.08 indicates that ALSMA has no problem at all paying its short term obligations.
ALSMA's Current ratio of 5.08 is amongst the best of the industry. ALSMA outperforms 94.34% of its industry peers.
ALSMA has a Quick Ratio of 4.25. This indicates that ALSMA is financially healthy and has no problem in meeting its short term obligations.
ALSMA has a Quick ratio of 4.25. This is amongst the best in the industry. ALSMA outperforms 94.34% of its industry peers.
Industry RankSector Rank
Current Ratio 5.08
Quick Ratio 4.25
ALSMA.PA Yearly Current Assets VS Current LiabilitesALSMA.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2M 4M 6M 8M 10M

More info and screens

6

3. Growth

3.1 Past

The earnings per share for ALSMA have decreased strongly by -24.01% in the last year.
Looking at the last year, ALSMA shows a decrease in Revenue. The Revenue has decreased by -4.09% in the last year.
The Revenue has been growing by 114.98% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-24.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-209.52%
Revenue 1Y (TTM)-4.09%
Revenue growth 3Y83.56%
Revenue growth 5Y114.98%
Sales Q2Q%-44.7%

3.2 Future

The Earnings Per Share is expected to grow by 43.88% on average over the next years. This is a very strong growth
ALSMA is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 32.39% yearly.
EPS Next Y-70.21%
EPS Next 2Y23.77%
EPS Next 3Y43.88%
EPS Next 5YN/A
Revenue Next Year2.79%
Revenue Next 2Y38.75%
Revenue Next 3Y39.74%
Revenue Next 5Y32.39%

3.3 Evolution

Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
ALSMA.PA Yearly Revenue VS EstimatesALSMA.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10M 20M 30M
ALSMA.PA Yearly EPS VS EstimatesALSMA.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 0 0.2 -0.2 0.4 -0.4 0.6

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALSMA. In the last year negative earnings were reported.
Also next year ALSMA is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ALSMA.PA Price Earnings VS Forward Price EarningsALSMA.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALSMA.PA Per share dataALSMA.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1 1.5

4.3 Compensation for Growth

A more expensive valuation may be justified as ALSMA's earnings are expected to grow with 43.88% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y23.77%
EPS Next 3Y43.88%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALSMA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SMAIO SA

EPA:ALSMA (5/9/2025, 7:00:00 PM)

4.04

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)N/A N/A
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap21.13M
Analysts84.44
Price Target6.12 (51.49%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)3.45%
PT rev (3m)3.45%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.3
P/FCF N/A
P/OCF N/A
P/B 2.63
P/tB 3.59
EV/EBITDA N/A
EPS(TTM)-0.34
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.66
FCFYN/A
OCF(TTM)-0.42
OCFYN/A
SpS0.94
BVpS1.53
TBVpS1.13
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -14.21%
ROE -22.35%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 88.45%
FCFM N/A
ROA(3y)-2.24%
ROA(5y)-17.04%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-3.69%
GM growth 5Y-4.68%
F-Score1
Asset Turnover0.39
Health
Industry RankSector Rank
Debt/Equity 0.31
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 83.63%
Cap/Sales 25.2%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 5.08
Quick Ratio 4.25
Altman-Z 3.16
F-Score1
WACC7.75%
ROIC/WACCN/A
Cap/Depr(3y)92.26%
Cap/Depr(5y)157.16%
Cap/Sales(3y)36.32%
Cap/Sales(5y)86.34%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-24.01%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-209.52%
EPS Next Y-70.21%
EPS Next 2Y23.77%
EPS Next 3Y43.88%
EPS Next 5YN/A
Revenue 1Y (TTM)-4.09%
Revenue growth 3Y83.56%
Revenue growth 5Y114.98%
Sales Q2Q%-44.7%
Revenue Next Year2.79%
Revenue Next 2Y38.75%
Revenue Next 3Y39.74%
Revenue Next 5Y32.39%
EBIT growth 1Y-100.1%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year16.13%
EBIT Next 3Y56.14%
EBIT Next 5YN/A
FCF growth 1Y-170.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-137.93%
OCF growth 3YN/A
OCF growth 5YN/A